Bank of New York Mellon
CADL icon

Bank of New York Mellon’s Candel Therapeutics CADL Stock Holding History

Bank of New York Mellon’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.97M Buy
191,701
+55,435
+41% +$419K ﹤0.01% 2959
2026
Q1 		$668K Buy
136,266
+41,058
+43% +$223K ﹤0.01% 3454
2025
Q4 		$538K Buy
95,208
+639
+0.7% +$3.44K ﹤0.01% 3573
2025
Q3 		$482K Buy
94,569
+7,765
+9% +$44.9K ﹤0.01% 3617
2025
Q2 		$439K Buy
86,804
+26,045
+43% +$134K ﹤0.01% 3578
2025
Q1 		$343K Buy
60,759
+15,779
+35% +$129K ﹤0.01% 3647
2024
Q4 		$390K Buy
44,980
+2
+0% +$12 ﹤0.01% 3645
2024
Q3 		$312K Sell
44,978
-9,471
-17% -$58.8K ﹤0.01% 3744
2024
Q2 		$338K Buy
+54,449
New +$409K ﹤0.01% 3769

Other funds holding CADL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Bank of New York Mellon's CADL Position: Q2 2026 in Review

Bank of New York Mellon increased its Candel Therapeutics (CADL) stake by 41% in Q2 2026, buying an estimated $419K and bringing the position to 191,701 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

Bank of New York Mellon first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. 52 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Bank of New York Mellon held 191,701 shares of Candel Therapeutics worth $1.97M as of Q2 2026.
  • Bank of New York Mellon bought 55,435 Candel Therapeutics shares in Q2 2026, an estimated $419K.
  • Candel Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2959 holding.
  • Bank of New York Mellon first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 52 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.